MorphoQuant® algorithms provide an unparallel precision and accuracy in the quantification of histology


MorphoQuant : A turnkey solution!

Biocellvia is an artifical-intelligence company specialized in image analysis, with a strong expertise in digital pathology. Its technology MorphoQuant™, provides objective quantification of pathological features for both preclinical and clinical studies using morphometric analysis.

For each therapeutic area, our specific algorithms were developed by digital imaging specialists and biologists, based on relevant histology. We identify morphometric parameters, quantify them, providing you with a more evident go/no-go decision for your drug candidate. This fully automated, proven and published methodology relies on field-proven-image-processing methods thereby ensuring that researchers obtain the most robust and reproducible data.

  • MorphoQuant is an AI-based technology, relying on morphometric recognition. As a non machine-learning or deep-learning tool, Biocellvia’s software is independent of human’s subjectivity and variability. The whole process of image analysis is fully automatized, from detection of section to quantitative data.
  • Moreover, our digital pathology software uses whole slide images, with no prior selection of potential areas of interest, allowing a better comprehensiveness of the assessment.
  • To ensure reliability and inter- and intra-study comparison , Biocellvia has standardized histology with development of specific stains and labels combinations to bring objectivity to our measurements.
  • MorphoQuant is also a reliable tool to support the development of non invasive imaging techniques, as a quantitative alternative to visual scoring.
Discover our Portfolio

Unreliable data leads to the failure of drug candidates *

The cost of these failures in terms of finances, lost time and impact on patients is enormous.

The heart of the problem lies in the preclinical models used to evaluate efficacy. These models do not translate well to human disease and are assessed using age-old, qualitative methods that often mask a molecule’s efficacy or lack thereof.

As an example; for NASH the use of pathologist-scored models provides researchers with a qualitative assessment of a molecule’s efficacy. This assessment is subjective, based on a limited area of the sample and is hugely imprecise. The lack of precision and accuracy of this analysis added to the 4-6 weeks that it takes to get this data across a whole study further erode the value of these models.

from pre-clinical stage

of drug candidates fail to get approved*.

from clinical stage

of these failures are due to lack of efficacy in the clinic*.

*Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results Thomas J. Hwang, AB; Daniel Carpenter, PhD; Julie C. Laffenburger, PhD et al. JAMA Internet. Med. 2016

Biocellvia’s unique digital pathology technology banishes variability and brings absolute accuracy to your efficacy data

Our fully automated quantitative assessment plays a critical role by providing researchers with absolute accuracy and precision, delivering results that bring more in-depth insights into their compounds’ efficacy.

Fast turn around time

Results are delivered within 72h.


no bias to the results leading to a better decision making

Scientific support

Project management

Highly accurate, precise and translational

data allowing true comparisons across the development continuum

Augmented pathology image

of each quantified feature for deeper understanding


logo biocellvia

on Linkedin

We keep you informed about interesting applications,
important dates and innovations through regular updates.

Follow us